AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8829939
Drug: ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 30 mg intramuscularly (i.m.)
Trial: 8829939
Drug: diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 50 mg orally
Trial: 8829939
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL NaCl i.m.
Trial: 31995688
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (lansoprazole [30 mg], amoxicillin [1000 mg], and clarithromycin [500 mg], each taken twice daily for 7 days)
Trial: 31995688
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events in treatment group
Trial: 30243993
Drug: Elevated Syndecan-1
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elevated Syndecan-1 levels (≥ 40 ng/mL)
Trial: 22414352
Drug: Transpapillary injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transpapillary injection
Trial: 22414352
Drug: Conventional palatal
RxNorm normalized name: malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional palatal injection
Trial: 20814766
Drug: Alpha-linolenic acid
RxNorm normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-linolenic acid (ALA) intake (1.2-3.6 g/d)
Trial: 17692522
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (5000lx, 100 cm distance)
Trial: 15866495
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg AJA
Trial: 1828420
Drug: Amlodipine 2.5
RxNorm normalized name: amlodipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 2.5 mg
Trial: 1693732
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 10 mg
Trial: 1414299
Drug: Indomethacin 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 1% ophthalmic solution
Trial: 2865930
Drug: PMP +
RxNorm normalized name: C(PMP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMP + D-penicillamine (DPA) - 500 mg/day
Trial: 2865930
Drug: PMP +
RxNorm normalized name: C(PMP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMP + sulphasalazine (SAS) - 2.0 g/day
Trial: 28631896
Drug: 0.75% Boric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% Boric acid gel
Trial: 24801644
Drug: Infusion set
RxNorm normalized name: INFUSION SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion set placed on the buttock
Trial: 24801644
Drug: Infusion set
RxNorm normalized name: INFUSION SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion set placed on the abdomen
Trial: 20237221
Drug: Various proposed
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various proposed solutions to improve value in cancer care; specific interventions not detailed.
Trial: 16162440
Drug: Ciprofibrate treatment
RxNorm normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate treatment
Trial: 12941195
Drug: Adjuvant hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy using goserelin (LHRH agonist)
Trial: 12941195
Drug: Adjuvant hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy using bilateral orchiectomy
Trial: 12941195
Drug: Adjuvant hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy using bicalutamide 150 mg
Trial: 12941195
Drug: LHRH agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonists (e.g., goserelin)
Trial: 10380836
Drug: Intermittent cyclical
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cyclical etidronate (400 mg daily for 2 weeks) and calcium (500 mg daily for 11 weeks)
Trial: 8671814
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum insulin concentration
Trial: 8671814
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum insulin concentration and diuretic therapy
Trial: 2065824
Drug: Intensive neurodevelopmental
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive neurodevelopmental therapy (NDT)
Trial: 2065824
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy alone
Trial: 21055143
Drug: Regular therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular therapy
Trial: 6173900
Drug: Concurrent control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent control group
Trial: 30118533
Drug: Computer-Assisted Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-Assisted Implant Planning and Placement (CAIPP) - Test 1 (T1, n = 24)
Trial: 30118533
Drug: Computer-Assisted Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-Assisted Implant Planning and Placement (CAIPP) - Test 2 (T2, n = 23)
Trial: 26806668
Drug: Minute ventilation-targeted
RxNorm normalized name: Tagetes minuta flower oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minute ventilation-targeted adaptive servo-ventilation (MV-ASV) during sleep in addition to optimized medical therapy (active therapy)
Trial: 26806668
Drug: Optimized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized medical therapy alone (usual care)
Trial: 25153328
Drug: Daily liquorice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily liquorice consumption (glycyrrhizin dose 290‐370 mg) for two weeks
Trial: 22774385
Drug: Weekly lectures
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly lectures by clinical experts (Control group).
Trial: 19930245
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of propofol 2 mg/kg with supplemental doses of 0.5 mg/kg as needed, followed by normal saline infusion at 0.3 ml/kg/h.
Trial: 19930245
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of propofol after initial sedation.
Trial: 16334716
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with point-injection therapy
Trial: 16334716
Drug: Basic neural
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic neural medical treatment
Trial: 10598967
Drug: AV node
RxNorm normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV node ablation and pacemaker implantation after discontinuation of rate-control medications
Trial: 10598967
Drug: AV node
RxNorm normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV node ablation and pacemaker implantation without discontinuation of antiarrhythmic rate-control drugs
Trial: 10598967
Drug: Pacemaker implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacemaker implantation without AV node ablation and continuing rate-control medical therapy
Trial: 7564786
Drug: Randomised consent
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised consent to experimental treatment
Trial: 7564786
Drug: Randomised consent
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised consent to standard treatment
Trial: 2009781
Drug: Low-dose amrinone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amrinone (0.75 mg/kg loading dose + 10 micrograms/kg/min infusion)
Trial: 2009781
Drug: High-dose amrinone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amrinone (2.25 mg/kg loading dose + 20 micrograms/kg/min infusion)
Trial: 30919382
Drug: Early P2Y12
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early P2Y12 inhibitor loading (clopidogrel)
Trial: 29975953
Drug: Thalidomide plus
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide plus chemotherapy (CAG regimen with thalidomide at a maximum dose of 200 mg/day)
Trial: 29975953
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (PC) - non‐intensive regimen composed of cytarabine, aclarubicin and G‐CSF (CAG) chemotherapy
Trial: 29975953
Drug: Thalidomide plus
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide plus chemotherapy
Trial: 24739131
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/day for 8 weeks
Trial: 24739131
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/day and 20 mg/day for 8 weeks
Trial: 22824595
Drug: Preoperative subconjunctival
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative subconjunctival injection of mitomycin C (0.1 ml of 0.15 mg/ml) a day before surgery
Trial: 22824595
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of mitomycin C during surgery (same concentration)
Trial: 22824595
Drug: Preoperative subconjunctival
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative subconjunctival injection of mitomycin C
Trial: 19015231
Drug: Adjunctive antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive antidepressant treatment for bipolar depression
Trial: 20854115
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) therapy
Trial: 1597230
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (100 micrograms.min‐1)
Trial: 31374191
Drug: Monthly coaching
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly coaching by physiotherapists encouraging 30 minutes of daily physical activity and 45-60 minutes of weekly exercise
Trial: 25638011
Drug: secukinumab 30
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 30 mg/kg IV
Trial: 25638011
Drug: secukinumab 10
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: secukinumab 10 mg/kg IV
Trial: 25638011
Drug: secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 300 mg SC
Trial: 18830553
Drug: Preemptive local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive local analgesia (PLA) with 20 ml of 0.5% bupivacaine with 1:200,000 epinephrine
Trial: 15035516
Drug: 150 mL
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mL of iopamidol (300 mgI/mL) at 5 mL/second
Trial: 15035516
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of iopamidol (370 mgI/mL) at 4 mL/second
Trial: 9743440
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30 mg starting dose, 60 mg maintenance dose once daily)
Trial: 2737602
Drug: Heat-inactivated hepatitis
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated hepatitis B vaccine with HBsAg complexed by anti-HBs in hepatitis B immunoglobulin at equivalent proportions
Trial: 2737602
Drug: Heat-inactivated hepatitis
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated hepatitis B vaccine with HBsAg complexed by anti-HBs in hepatitis B immunoglobulin at 10-fold antigen excess
Trial: 2737602
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine with standard dosage of HBsAg (3 micrograms)
Trial: 29625841
Drug: Adjuvant gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant gemcitabine 1000 mg/m2 on days 1, 8, 15 every 4 weeks for six cycles (group A)
Trial: 29625841
Drug: Adjuvant PEXG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant PEXG (cisplatin 30 mg/m2, epirubicin 30 mg/m2, and gemcitabine 800 mg/m2 on days 1 and 15 every 4 weeks and capecitabine 1250 mg/m2 on days 1-28) (group B)
Trial: 26328588
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) therapy with 40 mg pantoprazole b.i.d.
Trial: 22699302
Drug: Anamorelin 50
RxNorm normalized name: Anamorelin
DrugBank: Anamorelin (DB06645)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Anamorelin 50 mg/day
Trial: 19289630
Drug: Gefitinib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 500 mg/day
Trial: 12897327
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg or 500 mg daily)
Trial: 11502792
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oral androstenedione
Trial: 11502792
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral androstenedione
Trial: 11502792
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral androstenedione
Trial: 8321259
Drug: Intrathecal chemotherapy
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal chemotherapy during the first year; cranial irradiation and intrathecal chemotherapy one year after remission for high-risk patients
Trial: 8321259
Drug: Intrathecal injections
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal injections of chemotherapeutic agents and cranial irradiation for patients with central nervous system leukemia at diagnosis
Trial: 23349557
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of ALA after 10 days of oral ingestion (Group C)
Trial: 23349557
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of ALA (single dose) (Group B)
Trial: 21140562
Drug: Cytoflavin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin as a supporting drug in CAF chemotherapy
Trial: 21140562
Drug: CAF chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF chemotherapy
Trial: 7631729
Drug: Modified Pereyra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Pereyra needle suspension
Trial: 1497046
Drug: Home uterine
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home uterine activity monitoring and daily midwife contact
Trial: 11826422
Drug: Amantadine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine therapy
Trial: 350129
Drug: Amantadine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine alone or added to stable dose of levodopa
Trial: 350129
Drug: Levodopa alone
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa alone or added to stable dose of amantadine
Trial: 350129
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of amantadine a day
Trial: 350129
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of amantadine a day
Trial: 26115203
Drug: Gastroretentive gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastroretentive gabapentin (G‐GR) 1,800 mg once daily
Trial: 24118500
Drug: Supervised injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised injectable heroin treatment
Trial: 24118500
Drug: Supervised injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised injectable methadone treatment
Trial: 24118500
Drug: Optimised oral
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised oral methadone treatment
Trial: 21784729
Drug: golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 50 mg plus MTX
Trial: 22127693
Drug: golimumab 100
RxNorm normalized name: golimumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 100 mg plus MTX
Trial: 17061598
Drug: Multi-injection thoracic
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-injection thoracic paravertebral anesthesia (TPVA) with intravenous sedation
Trial: 16915030
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day irbesartan
Trial: 12820855
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose CT examination
Trial: 7718370
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections (IMI)
Trial: 7257433
Drug: Metronidazole preoperative
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole preoperative preparation
Trial: 28737425
Drug: Conventional buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional buccal orthodontics (20 patients)
Trial: 20975285
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with high MPL content
Trial: 20975285
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with lower MPL content
Trial: 12867568
Drug: Early high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early high-dose steroids and nasal CPAP ventilation
Trial: 12867568
Drug: Other three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other three treatment groups (not specified)
Trial: 11336083
Drug: Manidipine 10
RxNorm normalized name: manidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine 10 mg/day
Trial: 11336083
Drug: Delapril 30
RxNorm normalized name: Delapril
DrugBank: Delapril (DB13312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delapril 30 mg/day
Trial: 24465156
Drug: MMP (multi‐ingredient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMP (multi‐ingredient pre‐exercise workout supplement blend of creatine, betaine and a dendrobium extract)
Trial: 18724865
Drug: Periodontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal therapy with or without the use of antibiotics
Trial: 18724865
Drug: Implant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant therapy in subjects with diabetes
Trial: 15842586
Drug: K-Canrenoate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-Canrenoate (200 mg/day for 6 months)
Trial: 15842586
Drug: No-drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-drug treatment (control group)
Trial: 14699226
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg) and Metoclopramide (10 mg)
Trial: 2258632
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta
Trial: 28423407
Drug: Web-mediated follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-mediated follow-up algorithm based on weekly self-scored patient symptoms
Trial: 17301652
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg ATP administered through a naso-intestinal tube
Trial: 17301652
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered through a naso-intestinal tube